Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence through daily updates, research reports, and stock screens [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, serving as complementary indicators to the Zacks Rank [2][3] - Each stock receives a rating from A to F, with A indicating the highest potential for outperforming the market [3] Value Score - The Value Style Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3][4] Growth Score - The Growth Style Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [4] Momentum Score - The Momentum Style Score assesses stocks based on price trends and earnings estimate changes to identify favorable buying opportunities [5] VGM Score - The VGM Score combines the Value, Growth, and Momentum Scores, providing a comprehensive indicator for stock selection [6] Zacks Rank - The Zacks Rank utilizes earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988 [7][8] - There are over 800 top-rated stocks available, making it essential to use Style Scores for effective selection [9] Stock to Watch: Krystal Biotech, Inc. (KRYS) - Krystal Biotech is a biotechnology company focused on genetic medicines, currently holding a 2 (Buy) Zacks Rank and a VGM Score of B [12] - The company has seen a 17.1% increase in shares over the past four weeks, with upward revisions in earnings estimates for fiscal 2025 [12][13] - The Zacks Consensus Estimate for KRYS has risen by $1.06 to $7.06 per share, with an average earnings surprise of 3.3% [13]